Nifakos v. Secretary of Health and Human Services

CourtUnited States Court of Federal Claims
DecidedNovember 2, 2020
Docket14-236
StatusPublished

This text of Nifakos v. Secretary of Health and Human Services (Nifakos v. Secretary of Health and Human Services) is published on Counsel Stack Legal Research, covering United States Court of Federal Claims primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nifakos v. Secretary of Health and Human Services, (uscfc 2020).

Opinion

In the United States Court of Federal Claims OFFICE OF SPECIAL MASTERS No. 14-236V

************************* * VICTORIA NIFAKOS, * TO BE PUBLISHED * Petitioner, * Special Master Katherine E. Oler * v. * Filed: September 15, 2020 * SECRETARY OF HEALTH AND * HUMAN SERVICES, * Attorneys’ Fees & Costs; * Reasonable Basis Respondent. * ************************* *

Mark T. Sadaka, Mark T. Sadaka, LLC, Englewood, N.J., for Petitioner. Ida Nassar, U.S. Department of Justice, Washington, D.C., for Respondent.

DECISION ON MOTION FOR INTERIM ATTORNEYS’ FEES AND COSTS1

On March 27, 2014, Victoria Nifakos (“Petitioner”) filed a petition for compensation in the National Vaccine Injury Compensation Program (“the Vaccine Program”),2 alleging that she suffered non-Hodgkin’s lymphoma that was caused or significantly aggravated by her receipt of the Hepatitis A, Menactra, Varivax, and human papillomavirus (HPV) vaccinations on June 29, 2011. Pet. at 1, ECF No. 1.

Pursuant to the agreement of the parties, an entitlement hearing was held on June 18 and 19, 2019. See Non-PDF Minute Entry of June 19, 2019. Petitioner now requests a second award of interim attorneys’ fees and costs. Fees App., ECF No. 127 (Aug. 21, 2020).

1 This Decision will be posted on the Court of Federal Claims’ website. This means the Decision will be available to anyone with access to the internet. As provided by 42 U.S.C. § 300aa-12(d)(4)(B), however, the parties may object to the Decision’s inclusion of certain kinds of confidential information. Specifically, under Vaccine Rule 18(b), each party has fourteen days within which to request redaction “of any information furnished by that party: (1) that is a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of privacy.” Vaccine Rule 18(b). If, upon review, I agree that the identified materials fit within this definition, I will redact such material from public access. Otherwise, the Decision in its present form will be available. Id. 2 The Vaccine Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3758, codified as amended at 42 U.S.C. §§ 300aa-10 through 34 (2012) (“Vaccine Act” or “the Act”). Individual section references hereafter will be to § 300aa of the Act (but will omit that statutory prefix). 1 For the reasons discussed below, I hereby GRANT IN PART Petitioners’ application and award a total of $89,757.03 in interim attorneys’ fees and costs.

I. Procedural History

On June 1, 2018, Petitioner requested an award of interim attorneys’ fees and costs. ECF No. 73. I subsequently granted in part Petitioner’s motion, deferring the issue of Dr. Shoenfeld’s expert fees until the conclusion of entitlement proceedings. See Nifakos v. Sec’y of Health & Human Servs., 2018 U.S. Claims LEXIS 1936 at *9 (Dec. 12, 2018). On July 20, 2020, Petitioner filed a status report requesting that Dr. Shoenfeld’s expert fees now be granted, as the entitlement hearing had concluded. ECF No. 124 at 1. Subsequently, I held a status conference in this case on July 23, 2020. See Scheduling Order of July 23, 2020 at 1, ECF No. 126. At this status conference, I explained to Mr. Sadaka that as a general rule, I do not issue more than one decision on interim fees in a case, for reasons of judicial economy. However, I noted that due to the current Covid-19 pandemic, I understood some practitioners were currently experiencing financial hardship. Id. at 1.

Mr. Sadaka explained that his firm was currently experiencing financial hardship due to the Covid-19 pandemic, and that due to such hardship, he had thus far only been able to make a partial payment to Dr. Shoenfeld. ECF No. 126 at 1. Accordingly, on August 21, 2020, Petitioner submitted a second motion for interim fees and costs, requesting $62,822.57 in attorneys’ fees and $30,475.59 in costs, for a total of $93,298.16. Fees App., Ex. A at 12, ECF No. 127 (Aug. 21, 2020).

Respondent filed a response to Petitioner’s Motion on September 4, 2020. Fees Resp., ECF No. 128 (Sept. 4, 2020). Respondent argues that “[n]either the Vaccine Act nor Vaccine Rule 13 contemplates any role for [R]espondent in the resolution of a request by a petitioner for an award of attorneys’ fees and costs.” Id. at 1. Respondent adds, however, that he is “satisfied that the statutory requirements for an award of attorney’s fees and costs are met in this case.” Id. at 2. Additionally, he “respectfully recommends that [I] exercise [my] discretion and determine a reasonable award for interim attorneys’ fees and costs.” Id. at 3.

II. Legal Standard

A. Interim Attorneys’ Fees and Costs

The Federal Circuit has held that an award of interim attorneys’ fees and costs is permissible under the Vaccine Act. Shaw v. Sec’y of Health & Human Servs., 609 F.3d 1372 (Fed. Cir. 2010); Avera v. Sec’y of Health & Human Servs., 515 F.3d 1343 (Fed. Cir. 2008). In Cloer, the Federal Circuit noted that “Congress [has] made clear that denying interim attorneys' fees under the Vaccine Act is contrary to an underlying purpose of the Vaccine Act.” Cloer v. Sec’y of Health & Human Servs., 675 F.3d 1358, 1361-62 (Fed. Cir. 2012).

In Avera, the Federal Circuit stated, “[i]nterim fees are particularly appropriate in cases where proceedings are protracted, and costly experts must be retained.” Avera, 515 F.3d at 1352. Likewise, in Shaw, the Federal Circuit held that “where the claimant establishes that the cost of

2 litigation has imposed an undue hardship and there exists a good faith basis for the claim, it is proper for the special master to award interim attorneys' fees.” 609 F.3d at 1375. Avera did not, however, define when interim fees are appropriate; rather, it has been interpreted to allow special masters discretion. See Avera, 515 F.3d; Kirk v. Sec’y of Health & Human Servs., No. 08-241V, 2009 WL 775396, at *2 (Fed. Cl. Spec. Mstr. Mar. 13, 2009); Bear v. Sec’y of Health & Human Servs., No. 11-362V, 2013 WL 691963, at *4 (Fed. Cl. Spec. Mstr. Feb. 4, 2013). Even though it has been argued that a petitioner must meet the three Avera criteria -- protracted proceedings, costly expert testimony, and undue hardship -- special masters have instead treated these criteria as possible factors in a flexible balancing test. Avera, 515 F.3d at 1352; see Al-Uffi v. Sec’y of Health & Human Servs., No. 13-956V, 2015 WL 6181669, at *7 (Fed. Cl. Spec. Mstr. Sept. 30, 2015).

A petitioner is eligible for an interim award of reasonable attorneys’ fees and costs if the special master finds that a petitioner has brought his petition in good faith and with a reasonable basis. §15(e)(1); Avera, 515 F.3d at 1352; Shaw, 609 F.3d at 1372; Woods v. Sec’y of Health & Human Servs, 105 Fed. Cl. 148 (2012), at 154; Friedman v. Sec’y of Health & Human Servs., 94 Fed. Cl. 323, 334 (2010); Doe 21 v. Sec’y of Health & Human Servs., 89 Fed. Cl. 661, 668 (2009); Bear, 2013 WL 691963, at *5; Lumsden v. Sec’y of Health & Human Servs., No. 97-588V, 2012 WL 1450520, at *4 (Fed. Cl. Spec. Mstr. Mar. 28, 2012).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Nifakos v. Secretary of Health and Human Services, Counsel Stack Legal Research, https://law.counselstack.com/opinion/nifakos-v-secretary-of-health-and-human-services-uscfc-2020.